Target intelligence / Profile preview

Yersinia pestis F1 antigen (F1 antigen)

Target
F1 antigen
Molecular classification
Bacterial capsular antigen, Chaperone/usher pathway antigen, Nonpilus protein polymer, Other
01

Overview

The **Yersinia pestis F1 antigen** is a surface capsular protein uniquely produced by the plague bacterium Yersinia pestis at mammalian body temperatures (≈37°C). It is a high-molecular-weight polymer composed solely of Caf1 subunits, assembled on the bacterial surface via the chaperone/usher pathway encoded by the caf operon (caf1, caf1M, caf1A, caf1R)[2][4][5][6][7][9]. The F1 capsule forms a fibrous layer around the bacterium, functioning primarily as a virulence factor that impedes phagocytosis by host immune cells, thereby facilitating immune evasion and enhancing pathogenicity[1][2][4]. It is a potent immunogen, capable of inducing strong antibody responses which make it a key component in subunit, recombinant, and fusion vaccines against bubonic and pneumonic plague[9][10]. F1 antigen (alone or as part of fusion proteins, e.g., rF1-V) is widely used in vaccine efforts and basic immunological assays for the diagnosis or immunomonitoring of plague[9][10]. There are no significant direct safety concerns with the antigen itself beyond standard vaccine considerations.

Other names
F1 capsule antigenFraction 1 antigenCaf1 antigenF1 capsular antigen
02

Mechanism of action

Immune system stimulation (vaccination: F1 antigen induces rapid protective humoral and B cell responses against Y. pestis)[9] Antibody-mediated opsonization (naturally occurring or vaccine-induced antibodies promote bacterial clearance by phagocytosis)[1][9]

03

Biological functions

Immune evasion (phagocytosis resistance)Induction of protective immunityVirulence factorOther
04

Disease associations

Infection (specifically plague caused by Yersinia pestis)
05

Safety considerations

Typical protein vaccine safety concerns (hypersensitivity, reactogenicity)No inherent known toxicity, but improper manufacturing/purification could result in contaminants
06

Interacting drugs

Plague vaccines (rF1-V, RypVax, SV1, recombinant or subunit vaccines containing F1 antigen)
07

Biomarkers

Anti-F1 antibody titer (for immunization monitoring/diagnosis)

Beyond the preview

Go deeper on Yersinia pestis F1 antigen (F1 antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yersinia pestis F1 antigen (F1 antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call